Immune Response in Lung Cancer

N/ACompletedNCT01955343

Lithuanian University of Health Sciences100 enrolled

Overview

This study is designed to evaluate the importance of the immune cells localization (distribution) between malignant tumor islets and surrounding stroma and to investigate the associations between these immune cells as well as cytokines and clinicopathological and prognostic factors of non-small cell lung cancer (NSCLC) patients.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Lung Cancer

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) score of 0-1 * Patients with histologically documented non-small cell lung cancer * Control group - patients without non-small cell lung cancer * Written (signed) Informed Consent to participate in the study Exclusion Criteria: * Any other malignancies within 5 years * Any unstable systemic disease (including active infections, significant cardiovascular disease) * Prior chemotherapy or radiotherapy * Autoimmune disease * Nursing or pregnant women

Locations (1)

Lithuanian University of Health Sciences

Kaunas, Lithuania

Outcomes

Primary Outcomes

progression-free survival

Time frame: one year after enrolment to the study

Secondary Outcomes

overall survival

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.